See more : Soluna Holdings, Inc. (SLNH) Income Statement Analysis – Financial Results
Complete financial analysis of Energenesis Biomedical CO.,LTD. (6657.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Energenesis Biomedical CO.,LTD., a leading company in the Biotechnology industry within the Healthcare sector.
- China BlueChemical Ltd. (3983.HK) Income Statement Analysis – Financial Results
- Nouveau Holdings, Ltd. (NHLI) Income Statement Analysis – Financial Results
- Australis Oil & Gas Limited (ATS.AX) Income Statement Analysis – Financial Results
- Triller Group Inc. (ILLR) Income Statement Analysis – Financial Results
- NOW Inc. (0K9J.L) Income Statement Analysis – Financial Results
Energenesis Biomedical CO.,LTD. (6657.TW)
About Energenesis Biomedical CO.,LTD.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 7.16M | 7.35M | 7.49M | 7.08M | 6.25M |
| Cost of Revenue | 1.93M | 2.19M | 2.13M | 2.26M | 2.38M |
| Gross Profit | 5.23M | 5.17M | 5.36M | 4.83M | 3.87M |
| Gross Profit Ratio | 73.02% | 70.26% | 71.56% | 68.14% | 61.89% |
| Research & Development | 185.13M | 213.68M | 61.76M | 72.43M | 98.18M |
| General & Administrative | 74.91M | 59.24M | 61.96M | 60.58M | 52.41M |
| Selling & Marketing | 7.02M | 3.90M | 3.73M | 5.40M | 6.52M |
| SG&A | 81.94M | 63.14M | 65.69M | 65.98M | 58.93M |
| Other Expenses | 0.00 | 2.27M | -272.00K | 1.05M | 1.38M |
| Operating Expenses | 267.06M | 276.82M | 127.45M | 138.41M | 157.11M |
| Cost & Expenses | 269.00M | 279.01M | 129.58M | 140.67M | 159.49M |
| Interest Income | 0.00 | 3.93M | 2.41M | 3.41M | 2.67M |
| Interest Expense | 0.00 | 209.00K | 284.00K | 350.00K | 578.00K |
| Depreciation & Amortization | 17.26M | 24.41M | 22.90M | 19.97M | 17.86M |
| EBITDA | -244.58M | -241.04M | -97.05M | -109.16M | -131.34M |
| EBITDA Ratio | -3,416.83% | -3,279.04% | -1,295.90% | -1,541.55% | -2,101.04% |
| Operating Income | -261.84M | -265.46M | -119.95M | -129.13M | -149.20M |
| Operating Income Ratio | -3,657.96% | -3,611.14% | -1,601.71% | -1,823.60% | -2,386.74% |
| Total Other Income/Expenses | 1.46M | 5.99M | 1.85M | 4.11M | 3.47M |
| Income Before Tax | -260.38M | -265.66M | -120.24M | -129.48M | -149.77M |
| Income Before Tax Ratio | -3,637.64% | -3,613.98% | -1,605.50% | -1,828.54% | -2,395.98% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -260.38M | -265.66M | -120.24M | -129.48M | -149.77M |
| Net Income Ratio | -3,637.64% | -3,613.98% | -1,605.50% | -1,828.54% | -2,395.98% |
| EPS | -3.62 | -3.99 | -2.00 | -2.19 | -2.84 |
| EPS Diluted | -3.62 | -3.99 | -2.00 | -2.19 | -2.84 |
| Weighted Avg Shares Out | 72.02M | 66.63M | 60.05M | 59.07M | 52.74M |
| Weighted Avg Shares Out (Dil) | 72.02M | 66.63M | 60.05M | 59.07M | 52.74M |
Source: https://incomestatements.info
Category: Stock Reports